Europe
28 October 2025 The tech is being used to crunch thousands of documents in billion-dollar mediations and emerging as a valuable party at the table, finds Muireann Bolger.
15 October 2025
30 September 2025
Latest Features
Europe
As Big Pharma stalls investment in the UK, the government urgently needs to return to the negotiating table to salvage a key growth area, writes Tim Belcher of EIP.
Europe
In its first year, uptake of cases at the Unified Patent Court has surpassed most expectations. Darren Smyth of EIP delves into the facts and figures behind the headlines, with some surprising results.
Europe
It remains to be seen whether AI developers in the medical sector will benefit from the UK’s ‘flexible’ regulatory environment or find the lack of cohesion detrimental, say Jackie Mulryne and Beatriz San Martin of Arnold & Porter.
Europe
Is the court’s public access rule unfit for purpose? Lawyers at Mathys & Squire are arguing for pleadings and evidence to be automatically made available on request, finds Muireann Bolger.
Biotechnology
Recent clashes over patents covering modified guide RNAs have exposed different approaches from the US and Europe—and new complications for the field, says Claire Irvine of HGF.
Big Pharma
Despite a rocky start, with case-management issues and plenty of scepticism from stakeholders, there is much to applaud in the UPC’s first four months, write Sebastian Moore and John Lao of Herbert Smith Freehills.
Biotechnology
Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.
Big Pharma
Revocation and infringement actions involving a cholesterol treatment, prosthetic valves, and methods for analyte detection are among the first to land at the court within its first month, explain Joanne Welch and Darren Smyth of EIP.
More News
25 September 2025 A new survey from LSIPR reveals that European patent practitioners are grappling with client budget constraints and fast-evolving technologies, with most expecting patenting challenges to increase over the next five years.
25 September 2025 The General Court has handed a win to generic drug makers including Teva and Mylan in the battle over multiple sclerosis drug Tecfidera.
25 September 2025 The firm’s Technology & Engineering team will be expanded with an expert in patent drafting, prosecution and opposition/defence work across AI, digital health and medical devices.
23 September 2025 There are varying national eligibility requirements that distinguish between treatments of and diagnostics for animals and humans; it’s just a question of reformatting ‘method of treatment’ claims, write lawyers from Sterne Kessler.
18 September 2025 A UPC Court of Appeal decision establishes a new benchmark for what constitutes imminent infringement in pharmaceutical patent litigation, particularly regarding generics’ pre-launch preparations, writes Mike Gruber of Carpmaels & Ransford.
18 September 2025 From trademark decisions to judicial writing, the IP community is embracing AI but questions loom about quality, precedents, and jurisdictional limits. Muireann Bolger reports from Marques’ annual meeting.
9 September 2025 Wales’ first MP of ethnic minority background brings tech knowledge and expertise to the IP office, which is carrying out two pivotal consultations.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox